Cargando…

Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients

BACKGROUND: Pathological complete response (pCR) is the ultimate response in breast cancer patients treated with neoadjuvant chemotherapy (NCT). It might be a surrogate outcome for disease-free survival (DFS) and overall survival (OS). We studied the effect of clinical tumor stage (cT-stage) on tumo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goorts, Briete, van Nijnatten, Thiemo J. A., de Munck, Linda, Moossdorff, Martine, Heuts, Esther M., de Boer, Maaike, Lobbes, Marc B. I., Smidt, Marjolein L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387027/ https://www.ncbi.nlm.nih.gov/pubmed/28205044 http://dx.doi.org/10.1007/s10549-017-4155-2

Ejemplares similares

MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer
por: Goorts, Briete, et al.
Publicado: (2018)

Prediction of Primary Tumour and Axillary Lymph Node Response to Neoadjuvant Chemo(Targeted) Therapy with Dedicated Breast [18F]FDG PET/MRI in Breast Cancer
por: de Mooij, Cornelis M., et al.
Publicado: (2023)

Does the TNM classification of solitary internal mammary lymph node metastases in breast cancer still apply?
por: Habraken, V., et al.
Publicado: (2016)

MRI-Based Radiomics Analysis for the Pretreatment Prediction of Pathologic Complete Tumor Response to Neoadjuvant Systemic Therapy in Breast Cancer Patients: A Multicenter Study
por: Granzier, Renée W. Y., et al.
Publicado: (2021)

Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis
por: Ploumen, Roxanne A. W., et al.
Publicado: (2023)

Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study
por: van Nijnatten, Thiemo J. A., et al.
Publicado: (2017)

Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases
por: van Nijnatten, T. J. A., et al.
Publicado: (2017)

ASO Author Reflections: Preoperative Prediction of Postmastectomy Radiation Therapy After Neoadjuvant Systemic Therapy
por: Samiei, Sanaz, et al.
Publicado: (2019)

Conditional local recurrence risk: the effect of event-free years in different subtypes of breast cancer
por: Moossdorff, M., et al.
Publicado: (2021)

Value of (18)F-FDG PET/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype
por: de Mooij, Cornelis M., et al.
Publicado: (2021)

Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study
por: van Roozendaal, Lori M., et al.
Publicado: (2016)

The influence of neoadjuvant chemotherapy on complications of immediate DIEP flap breast reconstructions
por: Beugels, J., et al.
Publicado: (2019)

Differences in degree of lesion enhancement on CEM between ILC and IDC
por: van Nijnatten, Thiemo JA, et al.
Publicado: (2019)

Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis
por: Ploumen, Roxanne A. W., et al.
Publicado: (2023)

Diagnostic performance of standard breast MRI compared to dedicated axillary MRI for assessment of node-negative and node-positive breast cancer
por: Samiei, Sanaz, et al.
Publicado: (2020)

Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer
por: Vriens, B. E. P. J., et al.
Publicado: (2017)

Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis
por: Simons, Janine M., et al.
Publicado: (2019)

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
por: Swain, Sandra M., et al.
Publicado: (2019)

De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study
por: Simons, J. M., et al.
Publicado: (2020)

Can high school students help to improve breast radiologists in detecting missed breast cancer lesions on full-field digital mammography?
por: van Nijnatten, T.J.A., et al.
Publicado: (2019)

Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies
por: Vriens, Birgit E.P., et al.
Publicado: (2017)

Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
por: de Groot, S., et al.
Publicado: (2015)

Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy
por: van Roozendaal, L. M., et al.
Publicado: (2016)

Does conventional specimen radiography after neoadjuvant chemotherapy of breast cancer help to reduce the rate of second surgeries?
por: Schaefgen, Benedikt, et al.
Publicado: (2021)

Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients
por: de Mooij, Cornelis Maarten, et al.
Publicado: (2020)

Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction
por: Samiei, S., et al.
Publicado: (2019)

Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy
por: de Groot, A. F., et al.
Publicado: (2019)

The role of MRI in axillary lymph node imaging in breast cancer patients: a systematic review
por: Kuijs, V. J. L., et al.
Publicado: (2015)

Comparing the Diagnostic Performance of Contrast-Enhanced Mammography and Breast MRI: a Systematic Review and Meta-Analysis
por: Neeter, Lidewij M.F.H., et al.
Publicado: (2023)

Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial
por: Lugtenberg, Rieneke T., et al.
Publicado: (2020)

Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study
por: Murakami, Masatoshi, et al.
Publicado: (2022)

Applicability of magnetic seeds for target lymph node biopsy after neoadjuvant chemotherapy in initially node-positive breast cancer patients: data from the AXSANA study
por: Hartmann, Steffi, et al.
Publicado: (2023)

The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis
por: de Mooij, Cornelis M., et al.
Publicado: (2023)

Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study
por: Simons, Janine M., et al.
Publicado: (2020)

Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2022)

Dedicated Axillary MRI-Based Radiomics Analysis for the Prediction of Axillary Lymph Node Metastasis in Breast Cancer
por: Samiei, Sanaz, et al.
Publicado: (2021)

Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer
por: Skarping, Ida, et al.
Publicado: (2021)

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA
por: Tsuboi, Masahiro, et al.
Publicado: (2021)

Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
por: Iwata, Hiroji, et al.
Publicado: (2023)

The Quality of Tumor Size Assessment by Contrast-Enhanced Spectral Mammography and the Benefit of Additional Breast MRI
por: Lobbes, Marc B.I., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pm9i008h2miccrkab732r9p1lt